Email Print

How were the NVDPA Guidelines for absolute cardiovascular disease risk developed?

Answer

The absolute risk guidelines were developed according to the standards outlined in the NHMRC Standards and Procedures for Externally Developed Guidelines (2007)

Guidelines for the Assessment of Absolute Cardiovascular Disease Risk:
  1. A systematic review was completed in order to formulate recommendations (using literature up to April 2006). The resulting report, titled Technical report: review of the evidence and evidence-based recommendations for practice is available on NVDPA member websites.
  2. Where the systematic review identified insufficient evidence to answer a clinical question, a consensus-based approach was used to formulate recommendations. A steering group with broad representation completed this. Consensus statements were formulated based on available evidence (using literature up to August 2007) and expert clinical judgement. 
  3. Public consultation process to review the full guideline (April-May 2008). 
  4. Independent review of the full guideline by the National Health and Medical Research Council (NHMRC) (July-October 2008). 
  5. Finalisation of the guideline based on feedback from the review. 
  6. Endorsement by the NHMRC, received in January 2009. 
Guidelines for the Management of Absolute Cardiovascular Disease Risk:
  1. A systematic literature review was completed to answer pre-defined clinical questions. The search used literature from 2006 to June 2010 for the assessment of CVD risk, and 2002 to June 2010 for the remaining questions relating to management of absolute CVD risk. Hand searching was conducted between June 2010 and May 2011.  More information on the search strategy is available in the full guideline.
  2. Where the systematic review identified insufficient evidence to answer a clinical question, a consensus-based approach was used to formulate recommendations. A steering group with broad representation completed this. Consensus statements were formulated based on available evidence and expert clinical judgement. 
  3. The public consultation process invited feedback during a month-long period in April 2011.  A broad group of stakeholders, networks and consumer organisations were also invited to comment.
  4. Independent review of the full guideline by the National Health and Medical Research council (NHMRC).  
  5. Endorsement by RACGP and NHMRC, received in April 2012.

Category


An initiative of the National Vascular Disease Prevention Alliance

Heart Foundation
Stroke Foundation
www.cvdcheck.org.au